Advertisement
Advertisement
LRMR
Larimar Therapeutics, Inc. Common Stock
2.39
USDSponsored
+0.07
+3.02%
Nov 06, 15:59 UTC -5
Closed
After-Market
2.37
-0.02
-1.00%
Larimar Therapeutics, Inc. Common Stock (LRMR) Earnings
LRMR Earnings Reports
Positive Surprise Ratio
LRMR beat 27 of 40 last estimates.
68%
Next Report
Date of Next Report
Mar 17, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.38
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/-47.95%
Larimar Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 05, 2026, LRMR reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.35 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.02% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.38 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were Larimar Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Larimar Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Larimar Therapeutics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 3.02%, changed from $2.32 before the earnings release to $2.39 the day after.
When is Larimar Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 17, 2027.
What are the forecasts for Larimar Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Larimar Therapeutics, Inc. Common Stock is expected to report EPS of -$0.38 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.